Research

CJC 1295 Ipamorelin Dosage per Day With and Without DAC

How CJC-1295 with DAC differs from the version without it, what the 2006 human studies measured and why daily dosing charts have no evidence base.

Cover illustration for CJC 1295 Ipamorelin Dosage per Day With and Without DAC

CJC-1295 ipamorelin dosage per day is one of the most common questions about growth hormone peptides, yet it rests on a mix-up that few charts explain. The answer to any CJC-1295 ipamorelin dosage per day question depends first on which CJC-1295 is meant, because the version with DAC and the version without it behave like different drugs. This guide explains that difference, summarises the human studies that exist, looks at why daily charts do not match the evidence and reviews regulatory status. It is written for a research audience and is not medical advice.

CJC 1295 With and Without DAC Explained

CJC-1295 was described in the scientific literature in 2005 as a long acting version of growth hormone releasing hormone. Its core is the first 29 amino acids of the natural hormone, with four amino acid substitutions that make the chain harder for enzymes to break down. The original CJC-1295 also carries an extra reactive group attached to a lysine at one end. A 2005 study in rats showed that this group binds to albumin, the most common protein in blood, after injection. Bound to albumin, the peptide stayed in plasma for more than 72 hours instead of being cleared within minutes. Regulators and researchers call this add-on a drug affinity complex, or DAC, and it is the reason for the long action that defined the original compound.

The version sold as CJC-1295 without DAC is the same modified 29 amino acid chain without the albumin binding group. It is often marketed as modified GRF 1-29. Without albumin binding, it is expected to act for a much shorter time, closer to other GHRH fragments such as sermorelin. This is where confusion begins. The human studies of CJC-1295 used the long acting DAC form, while many products and charts online refer to the short acting form under the same name. Searches such as cjc dac dosage and cjc no dac dosage therefore describe two different molecules. A figure taken from research on one cannot be applied to the other, because their duration of action, and therefore their exposure over time, differs greatly.

CJC 1295 With DAC Dosage in Human Studies

Published human data on CJC-1295 come mainly from two papers in 2006, both using the DAC form in healthy adults. The first, by Teichman and colleagues, combined two randomised, placebo controlled trials lasting 28 and 49 days. Participants aged 21 to 61 received one of four ascending single doses, or two or three doses given weekly or every two weeks. A single injection raised growth hormone two to tenfold for six days or more and IGF-1 one and a half to threefold for 9 to 11 days. The estimated half-life was 5.8 to 8.1 days. The authors described the peptide as relatively well tolerated, particularly at 30 or 60 micrograms per kilogram.

StudyParticipantsFormAmounts givenKey finding
Teichman 2006Healthy adults, 21 to 61 yearsWith DAC, under the skinFour ascending single doses in the microgram per kilogram range, then repeated weekly or biweekly dosesHalf-life 5.8 to 8.1 days, IGF-1 raised for up to 28 days after repeated doses
Ionescu 2006Healthy men, 20 to 40 yearsWith DAC, under the skinSingle dose of 60 or 90 micrograms per kilogramGrowth hormone pulses preserved, trough levels 7.5 times higher
Without DACNo controlled human study foundNot applicableNo established doseNot applicable

The second study, by Ionescu and Frohman, sampled blood every 20 minutes overnight before and one week after a single injection. Growth hormone still rose and fell in pulses, but the low points between pulses were 7.5 times higher than before. Mean growth hormone rose by 46 percent and IGF-1 by 45 percent, with no clear difference between the two dose levels. These findings answer a narrow question about hormone patterns in healthy volunteers. They do not establish a CJC 1295 with DAC dosage for any outcome, because neither paper tested benefit, long term safety or use in patients. The doses describe study conditions, not a recommendation for anyone outside a trial.

CJC 1295 Ipamorelin Dosage per Day Claims

Online charts often present a CJC-1295 ipamorelin dosage chart with daily injections of both peptides. For the DAC form, a daily schedule does not match the published design at all. With a half-life of about a week, the studied regimens gave single doses or doses spaced a week or two apart, and IGF-1 stayed raised for days after each one. Daily use of a compound that lasts that long would lead to build up that no study has measured. A CJC-1295 dosage per day figure therefore usually refers to the short acting form without DAC, which has no controlled human dosing data. In other words, every CJC-1295 ipamorelin dosage per day chart relies on the version with the least evidence behind it.

Ipamorelin adds another layer of uncertainty. It acts on the ghrelin receptor rather than the GHRH receptor, which is why vendors pair it with CJC-1295. A phase 2 trial in patients gave it by intravenous infusion after bowel surgery and found no significant benefit over placebo on its main outcome. No published study has tested CJC-1295 and ipamorelin together in people, in any form or at any dose. So any CJC-1295 ipamorelin dosage on a vendor page, whether expressed per day, per week or by body weight, is built from guesswork rather than measured outcomes. For both forms, the accurate statement is the same. There is no established CJC-1295 dosage for human use outside the original research setting.

Regulatory Status and Safety Signals

Neither CJC-1295 nor ipamorelin is approved as a medicine. At a meeting on 4 December 2024, the FDA's Pharmacy Compounding Advisory Committee voted on five CJC-1295 substances, including the DAC forms, that had been nominated for the list of ingredients compounding pharmacies may use. The committee voted against every one, unanimously for most, and one member noted the lack of evidence for effectiveness. On its page about compounding substances that may pose significant safety risks, the FDA lists CJC-1295 among nominated and withdrawn substances and mentions serious adverse events including increased heart rate. Ipamorelin appears on the same page, where the agency cites a published report of serious adverse events, including death, after intravenous use.

Anti-doping rules are also clear. The World Anti-Doping Agency names CJC-1295 among prohibited GHRH analogues and ipamorelin among prohibited growth hormone secretagogues, banned at all times. Product quality is a further concern, since a vial labelled CJC-1295 may contain the DAC form, the form without DAC or neither, and buyers rarely have a way to check. That uncertainty alone makes a cjc 1295 dac dosage question impossible to answer from a label. For researchers, sound practice means confirming the exact molecule by independent analysis, choosing doses from published methods in a matching model and including controls. Charts that skip these steps add numbers without adding knowledge.

Conclusion

CJC-1295 ipamorelin dosage per day questions mix two molecules and two pathways. The DAC form binds albumin, has a half-life of about a week and was studied in healthy adults at single or weekly doses in the microgram per kilogram range. The form without DAC and the pairing with ipamorelin lack controlled human dosing data. Neither peptide is approved, FDA advisers voted against compounding CJC-1295, and both are prohibited in sport, so no established dose exists.

Sources

  1. PubMed, PMID 15817669
  2. PubMed, PMID 16352683
  3. PubMed, PMID 17018654
  4. PubMed, PMID 25331030
  5. U.S. FDA: Updated meeting time and public participation information december 4 2024 meeting pharmacy
  6. U.S. FDA document 185642
  7. U.S. FDA: Certain bulk drug substances use compounding may present significant safety risks
  8. World Natural Bodybuilding Federation: WNBF Educational Material PAAT S224 Growth Hormone Releasing Hormone Peptides 1
Educational only. This article does not replace advice from a doctor or pharmacist. Read the full disclaimer.
Peptide City Editorial

We explain how peptides work and what the evidence shows. Amounts are reported as study or label data, never as advice, and we never name sellers. How articles are checked.